Havrix

Havrix is a hepatitis A vaccine containing inactivated hepatitis A virus and the adjuvant algeldrate, supplied as an injectable solution for intramuscular administration. Marketed in the European Union, this product is formulated to stimulate active immunity against hepatitis A infection. The vaccine’s composition and delivery method are designed to generate protective antibodies after a standard vaccination schedule. Typically, two doses are given, spaced several weeks apart, to achieve long‑term protection.

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk or require immunization before travel, occupational exposure, or outbreak situations.

- Routine immunization of children and adults according to national hepatitis A vaccination schedules. - Pre‑travel protection for persons traveling to regions where hepatitis A is endemic. - Protection of laboratory personnel handling hepatitis A virus specimens. - Immunization of close contacts of confirmed hepatitis A cases to limit secondary transmission. - Use in outbreak control programs to rapidly increase community immunity.

The safety profile of Havrix reflects the typical reactions observed with injectable vaccines, ranging from mild, transient symptoms to rare, more serious events.

Common: - Pain, redness or swelling at the injection site. - Low‑grade fever. - Headache or mild fatigue. - Muscle aches. - Mild nausea. - Transient dizziness. - Mild rash at distant sites. - Temporary tingling sensation.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, or swelling of the face. - Guillain‑Barré syndrome, a rare neurological condition. - High fever lasting more than 48 hours. - Persistent joint pain or swelling. - Seizure (rare). - Autoimmune hepatitis (very rare). - Severe thrombocytopenia (rare). These reactions are generally self‑limiting and resolve without medical intervention.

Before receiving Havrix, certain health considerations should be reviewed to ensure safe administration and optimal immune response.

- Confirm no severe allergic reaction to any component of the vaccine, especially algeldrate. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Discuss pregnancy or breastfeeding status with a healthcare professional, as safety data are limited. - Evaluate immunocompromised patients, as vaccine response may be reduced. - Review any history of Guillain‑Barré syndrome following previous vaccinations. - Avoid vaccination in persons with a known bleeding disorder at the injection site without proper precautions.

Havrix does not have many documented drug interactions, but certain substances and medical conditions may influence its effectiveness or safety.

Avoid: - Live viral vaccines administered within 4 weeks before or after Havrix. - Immunoglobulin or blood products given within 2 weeks of vaccination, which may reduce antibody response. - High‑dose corticosteroids taken at the time of vaccination, as they can suppress immune response.

Use with caution: - Anticoagulant therapy, because intramuscular injection may increase bleeding risk. - Immunosuppressive agents (e.g., chemotherapy, biologics) – vaccine may be less effective. - Chronic liver disease – monitor for adequate immune response. - Pregnancy – discuss with clinician as data are limited.